|
influenza |
34 |
|
epidemiology |
18 |
|
vaccination |
17 |
|
public health |
16 |
|
25-hydroxyvitamin d |
14 |
|
vitamin d |
14 |
|
hong kong |
13 |
|
humans |
13 |
|
immunity |
13 |
|
child |
12 |
|
hong kong - epidemiology |
12 |
|
influenza virus |
12 |
|
nasopharyngeal carcinoma |
12 |
|
transmission |
12 |
|
children |
11 |
|
medical sciences |
11 |
|
pandemic |
11 |
|
pandemics |
11 |
|
case-control study |
10 |
|
epstein-barr virus |
10 |
|
incidence rates |
10 |
|
infection |
10 |
|
seasons |
10 |
|
airborne |
9 |
|
child, preschool |
9 |
|
contamination |
9 |
|
coronavirus |
9 |
|
dietary fiber |
9 |
|
disease outbreaks |
9 |
|
family characteristics |
9 |
|
family health |
9 |
|
fresh vegetable and fruit |
9 |
|
genetic epidemiology |
9 |
|
genetic variant |
9 |
|
influenza-virus |
9 |
|
life-course |
9 |
|
milk |
9 |
|
multiple imputation |
9 |
|
preserved food |
9 |
|
randomized controlled trial |
9 |
|
soybean product |
9 |
|
surveillance |
9 |
|
ultraviolet radiation |
9 |
|
vaccine |
9 |
|
viral shedding |
9 |
|
vitamin d deficiency |
9 |
|
adolescent |
8 |
|
antibody-dependent cellular cytotoxicity |
8 |
|
baseline immunity |
8 |
|
bioaerosol |
8 |
|
cigarette smoking |
8 |
|
dose-response relation |
8 |
|
ha stem antibodies |
8 |
|
human exhaled breath |
8 |
|
influenza a virus, h1n1 subtype - isolation and purification |
8 |
|
influenza virus infection |
8 |
|
influenza-like illness |
8 |
|
mask |
8 |
|
serology |
8 |
|
smoking cessation |
8 |
|
t cells |
8 |
|
universal immune correlate |
8 |
|
2009 h1n1 influenza |
7 |
|
antibody |
7 |
|
antibody titer |
7 |
|
asymptomatic |
7 |
|
clinical epidemiology |
7 |
|
infectiousness |
7 |
|
influenza a(h5n1) |
7 |
|
influenza a(h7n9) |
7 |
|
influenza vaccine |
7 |
|
male |
7 |
|
nose - virology |
7 |
|
orthomyxoviridae - isolation & purification |
7 |
|
pharynx - virology |
7 |
|
reverse transcriptase polymerase chain reaction |
7 |
|
acute respiratory illness |
6 |
|
age |
6 |
|
antibodies, neutralizing - blood |
6 |
|
antibodies, viral - blood |
6 |
|
avian influenza a (h7n9) |
6 |
|
behavior |
6 |
|
clinical diagnosis |
6 |
|
clinical prediction rule |
6 |
|
cross protection |
6 |
|
death |
6 |
|
descriptive epidemiology |
6 |
|
disease transmission |
6 |
|
environment |
6 |
|
female |
6 |
|
genetic variation |
6 |
|
h1n1 pandemic |
6 |
|
health knowledge, attitudes, practice |
6 |
|
hemagglutination inhibition tests |
6 |
|
hemagglutinin glycoproteins, influenza virus - genetics |
6 |
|
hospital emergency setting |
6 |
|
human influenza |
6 |
|
immunization (vaccination) |
6 |
|
influenza a virus, h1n1 subtype |
6 |
|
influenza a virus, h1n1 subtype - classification - genetics - isolation & purification |
6 |
|
influenza a virus, h3n2 subtype - classification - genetics - isolation & purification |
6 |
|
influenza b virus |
6 |
|
influenza vaccines - administration & dosage - immunology |
6 |
|
influenza, human - epidemiology - prevention & control - transmission |
6 |
|
influenza, human - epidemiology - prevention & control - virology |
6 |
|
influenza, human - epidemiology - prevention and control - psychology - virology |
6 |
|
influenza, human - epidemiology - virology |
6 |
|
isolation |
6 |
|
models, biological |
6 |
|
molecular sequence data |
6 |
|
neuraminidase - genetics |
6 |
|
neutralization tests |
6 |
|
oseltamivir |
6 |
|
pandemic h1n1 |
6 |
|
phylogeny |
6 |
|
placebos - administration & dosage |
6 |
|
population surveillance - methods |
6 |
|
prospective studies |
6 |
|
psychological and behavioral responses |
6 |
|
residence characteristics |
6 |
|
rna, viral - genetics - isolation & purification |
6 |
|
school |
6 |
|
schools |
6 |
|
sequence variation |
6 |
|
seriousness |
6 |
|
solar radiation |
6 |
|
statistics |
6 |
|
surface |
6 |
|
vaccination - methods |
6 |
|
vaccine effectiveness |
6 |
|
vaccines, inactivated - administration & dosage - immunology |
6 |
|
victoria lineage |
6 |
|
viral proteins - genetics |
6 |
|
yamagata lineage |
6 |
|
a(h7n9) |
5 |
|
absenteeism |
5 |
|
adult |
5 |
|
aged |
5 |
|
aged, 80 and over |
5 |
|
antibody response |
5 |
|
antiviral agents - therapeutic use |
5 |
|
berberine |
5 |
|
burden |
5 |
|
communicable diseases |
5 |
|
dashboard |
5 |
|
disease activity |
5 |
|
disease surveillance |
5 |
|
dissemination |
5 |
|
dynamics |
5 |
|
enzyme linked immunosorbent assay |
5 |
|
flu like syndrome |
5 |
|
genetic difference |
5 |
|
hospitalization |
5 |
|
illness |
5 |
|
immune response |
5 |
|
infant |
5 |
|
influenza, human - diagnosis - virology |
5 |
|
influenza, human - drug therapy - transmission - virology |
5 |
|
middle aged |
5 |
|
orthomyxoviridae - isolation and purification |
5 |
|
oseltamivir - therapeutic use |
5 |
|
outpatient |
5 |
|
seasonal influenza |
5 |
|
seasonality |
5 |
|
self-examination - methods |
5 |
|
severity |
5 |
|
symptom |
5 |
|
symptoms |
5 |
|
test-negative design |
5 |
|
testosterone |
5 |
|
time factors |
5 |
|
treatment outcome |
5 |
|
vaccine efficacy |
5 |
|
vaccine match |
5 |
|
virus shedding |
5 |
|
young adult |
5 |
|
acceptability |
4 |
|
acute respiratory infections |
4 |
|
asymptomatic cases |
4 |
|
chronic renal disease |
4 |
|
communication |
4 |
|
congenital duodenal obstruction |
4 |
|
contact tracing |
4 |
|
correlation |
4 |
|
delivery |
4 |
|
digital rt-pcr |
4 |
|
duodenal atresia |
4 |
|
duodenoduodenostomy |
4 |
|
environmental risk factors |
4 |
|
fomite |
4 |
|
h1n1 |
4 |
|
health care workers |
4 |
|
healthcare seeking behaviour |
4 |
|
healthcare workers |
4 |
|
indirect contact |
4 |
|
influenza activity |
4 |
|
influenza vaccines - administration and dosage - immunology |
4 |
|
influenza, human - diagnosis - epidemiology - transmission |
4 |
|
influenza, human - epidemiology - prevention and control - transmission - virology |
4 |
|
influenza, human - microbiology - prevention and control |
4 |
|
information dissemination |
4 |
|
internet |
4 |
|
laparoscopy |
4 |
|
mobile phone |
4 |
|
mode of transmission |
4 |
|
monitoring |
4 |
|
neonatal surgery |
4 |
|
object |
4 |
|
online systems |
4 |
|
orthomyxoviridae - immunology - isolation and purification |
4 |
|
outcomes |
4 |
|
pattern |
4 |
|
population screening |
4 |
|
predict |
4 |
|
prediction |
4 |
|
pregnancy |
4 |
|
reactogenicity |
4 |
|
renin inhibitor |
4 |
|
rt-pcr |
4 |
|
school absenteeism |
4 |
|
school attendance |
4 |
|
school-located influenza vaccination |
4 |
|
seasonal |
4 |
|
seroprevalence |
4 |
|
sickness absence |
4 |
|
subsidy |
4 |
|
surveillance tolls |
4 |
|
symptom-specific |
4 |
|
target groups |
4 |
|
transmissibility |
4 |
|
trend |
4 |
|
underlying risk factors |
4 |
|
years of life lost |
4 |
|
awareness |
3 |
|
behaviour |
3 |
|
biostatistics |
3 |
|
case-control studies |
3 |
|
correlation analysis |
3 |
|
epidemiologic studies |
3 |
|
healthcare personnel |
3 |
|
immunogenicity |
3 |
|
infection control - methods |
3 |
|
infectious disease |
3 |
|
infectious disease control |
3 |
|
infectious disease epidemiology |
3 |
|
infectious disease transmission, vertical - prevention and control |
3 |
|
influenza virus a h1n1 |
3 |
|
influenza, human - epidemiology - prevention and control - transmission |
3 |
|
masks - utilization |
3 |
|
occupational exposure |
3 |
|
respiratory protective devices - utilization |
3 |
|
solvents |
3 |
|
vaccination uptake |
3 |
|
antiviral |
2 |
|
artificial infant feeding |
2 |
|
breast milk |
2 |
|
breast milk substitutes |
2 |
|
breastfeeding |
2 |
|
ic50 |
2 |
|
infant feeding |
2 |
|
influenza b |
2 |
|
lineage |
2 |
|
lymphoid malignancies |
2 |
|
neuraminidase inhibitor |
2 |
|
non-hodgkin lymphoma |
2 |
|
supplementation |
2 |
|
airborne transmitted pathogens |
1 |
|
chinese |
1 |
|
emission strength |
1 |
|
infectious diseases |
1 |
|
migrants |
1 |
|
myeloma incidence |
1 |
|
size-resolved emissions |
1 |
|
toilet flushing-generated water droplets |
1 |
|
toilet hygiene |
1 |
